In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
On the occasion of World Hand Hygiene Day, 5th May, ECDC is releasing new web pages dedicated to the Healthcare-associated Infections Surveillance Network (HAI-Net) – a European network for HAI surveillance, coordinated by ECDC.
The authors retrospectively analyzed hepatitis A virus (HAV) seroprevalence in travellers who had been born and lived at least 1 year in a developing country, wanted to travel to a hepatitis A endemic area, and consulted at the vaccination centre of the Institut Pasteur of Paris between September 1, 2008 and February 28, 2010. HAV seroprevalence was 82.4 % for a population of 646 immigrants for whom data were available
Using surveillance data obtained from 21,888 imported Plasmodium falciparum cases in France during 1996-2003, factors independently associated with severe malaria (832 cases; ≈3.8%) were older age, European origin, travel to eastern Africa, absence of chemoprophylaxis, initial visit to a general practitioner, time to diagnosis of 4 to 12 days, and diagnosis during the fall-winter season.
This study describes the outcome of 25 travellers with severe malaria who returned from malaria-endemic regions and were treated at 7 centres in Europe with intravenous artesunate. Among these 25 patients, one child and 24 adults (mean ± SD age 44.1 ± 16.1 years), 10 patients received the dosing regimen for artesunate initially recommended by WHO and 11 received artesunate, 2.4 mg/kg/dose.
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.
The first annual meeting of the European hepatitis B and C surveillance network takes place on 23-24 March 2011. Since 2009, ECDC has worked on preparing the enhanced surveillance of hepatitis B and C at EU/EEA level by establishing a network for hepatitis B and C surveillance and by carrying out a survey on prevention and surveillance activities in the Member States.
ECDC and EFSA have just launched the annual report on zoonoses and food-borne outbreaks in the European Union for 2009. The report shows that Salmonella cases in humans fell by 17% in 2009, marking a decrease for the fifth consecutive year